# First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/first-line-nivolumab-plus-relatlimab-versus-nivolumab-plus-ipilimumab-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Georgina V. Long,Evan J. Lipson,F. Stephen Hodi,Paolo A. Ascierto,James Larkin,Christopher D. Lao,Jean‐Jacques Grob,Flavia Ejzykowicz,Andriy Moshyk,Viviana García-Horton,Zheng‐Yi Zhou,Yiqiao Xin,Jennell Palaia,Laura McDonald,Sarah Keidel,Anthony Salvatore,Divya Patel,Leon A. Sakkal,Hussein A. Tawbi,Dirk Schadendorf |
| Citations | 59 |
| DOI | 10.1200/jco.24.01125 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://ascopubs.org/doi/pdf/10.1200/JCO.24.01125 |
| OpenAlex ID | https://openalex.org/W4401533964 |
| PMID | 39137386 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Zheng‐Yi Zhou](https://scholariq.org/researchers/zheng-yi-zhou/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.